In his written statement to the Inquiry, Dr Lloyd commented that the RIBA II assay "appeared to substantially remove the issue of lack of specificity. Once the RIBA II test was available, the lack of specificity with the first-generation test would have been much more manageable".

Chronology Information

Date:

Chapter/issue
Hepatitis C Screening
Key Person(s)
Dr Huw Lloyd